



Green Tea Polyphenols and Isotretinoin Toxicity: A Critical Review of Hepatic and Male Reproductive Outcomes

Mennat Allah Ali Mohamed Adel, Mohamed Shehata , Ahmed Mobasher, Mahitab Mohamed Nageeb

Clinical Pharmacology Department, Faculty of Medicine, Zagazig University

Corresponding author: Mennat Allah Ali Mohamed Adel

Received: 28 October 2024, **Accepted:** 17 November 2024, **Published:** 20 November 2024

Abstract

Background: Isotretinoin remains an effective treatment for severe acne, but hepatic laboratory abnormalities and experimental testicular injury have stimulated interest in protective interventions. Green tea polyphenols possess biological activities relevant to these effects, although concentrated extracts can themselves produce hepatic injury. Aim: To critically evaluate the pharmacological rationale, hepatic and male reproductive evidence, and translational limitations of green tea polyphenols during isotretinoin exposure. Methods: This narrative review integrates verified experimental and clinical publications addressing isotretinoin safety, retinoid-dependent spermatogenesis, catechin pharmacology, and green tea extract toxicity. Evidence directly involving isotretinoin is distinguished from findings obtained with other toxicants or isolated cells. Results: Rodent studies associate isotretinoin exposure with oxidative damage, impaired seminiferous architecture, and increased germ-cell apoptosis. Human reproductive findings are heterogeneous; several studies report improved semen indices, while morphological changes and uncertain long-term outcomes require careful interpretation. Green tea catechins can influence redox balance, inflammatory signaling, and sperm metabolism, providing a plausible experimental basis for tissue protection. These actions depend on concentration, formulation, nutritional conditions, and cellular context. Inhibition of testosterone production in isolated Leydig cells and adverse effects at higher sperm exposure concentrations challenge assumptions of uniform reproductive benefit. Randomized supplementation studies and pharmacovigilance data also establish a clinically relevant hepatic safety concern. Conclusion: Green tea polyphenols warrant investigation as experimental modifiers of isotretinoin-associated injury, but available evidence does not establish clinical protection or justify routine supplementation. Standardized preparations, exposure measurements, functional reproductive outcomes, and controlled safety evaluation are necessary before therapeutic translation in patients receiving isotretinoin for acne.

Keywords: Isotretinoin, green tea polyphenols, hepatotoxicity, male reproductive function



Introduction

Isotretinoin occupies an unusual position in clinical pharmacology: its capacity to produce durable acne improvement is well established, while some proposed extracutaneous hazards remain difficult to translate from laboratory models into patient care. Current acne guidance strongly recommends oral isotretinoin for severe disease, scarring, substantial psychosocial burden, or failure of standard treatment. A review of protective interventions must therefore begin with its therapeutic value rather than assume that systemic exposure inevitably causes organ damage. The relevant question is whether an additional intervention can reduce a defined adverse outcome without compromising treatment effectiveness or introducing new toxicity. This distinction is especially important when considering biologically active botanical preparations. [1]

The pharmacological rationale for examining hepatic and testicular outcomes arises from retinoid metabolism and the sensitivity of reproductive differentiation to vitamin A signaling. Isotretinoin alters sebaceous gland activity, follicular keratinization, and inflammatory processes through mechanisms that involve conversion to active retinoid metabolites. Its systemic effects cannot be reduced to a single receptor interaction or a universal oxidative mechanism. Food-dependent absorption, formulation, daily exposure, treatment duration, and individual susceptibility affect interpretation of adverse events. Green tea polyphenols may modify processes downstream of tissue stress, but such activity does not establish that they antagonize the initiating retinoid effect. Separating these possibilities is essential to a credible protective hypothesis. [2]

This review evaluates hepatic and male reproductive outcomes associated with isotretinoin, examines the mechanistic and experimental basis for green tea polyphenols as potential modifiers, and identifies the conditions required for clinical translation. Its central research gap is the absence of established controlled human evidence demonstrating simultaneous hepatic and reproductive protection during isotretinoin treatment.

Hepatic outcomes during isotretinoin treatment

Clinical hepatic safety is best interpreted by distinguishing modest enzyme changes from consequential liver injury. In their systematic review and meta-analysis, Lee and colleagues found changes in several laboratory indices during isotretinoin treatment, but average values generally did not reach predefined high-risk levels and serious abnormalities were uncommon. These observations challenge an interpretation in which every rise in alanine aminotransferase represents progressive hepatotoxicity. They also affect intervention design: preventing small laboratory fluctuations is a different objective from preventing clinically significant injury. Baseline abnormalities, concurrent medication, alcohol exposure, metabolic disease, and laboratory variability should be considered before attributing an individual change exclusively to isotretinoin. [3]

A population-based analysis provides useful absolute-risk context. Emtenani and colleagues compared 79,012 isotretinoin initiators with an equal number of patients prescribed oral antibiotics. During the first three months, grade 3 or greater hypertriglyceridemia and aspartate aminotransferase elevation occurred in approximately 0.4% and 0.2% of isotretinoin recipients, respectively. Corresponding excess risks were three and one additional cases per 1,000 treated patients. Severe alanine aminotransferase abnormalities did not show a significant increase. Most disturbances appeared within one to three months. These findings support early surveillance while showing why a clinical hepatoprotection trial would need a carefully chosen endpoint and adequate sample size. [4]

Monitoring practice further illustrates the difference between mechanistic concern and clinical burden. An international Delphi study supported checking alanine aminotransferase and triglycerides before treatment and at peak isotretinoin dosage rather than performing monthly testing in every uncomplicated patient. This consensus concerns ordinary clinical management, not experimental coadministration of a potentially hepatotoxic extract. A trial introducing green tea supplementation should therefore establish its own safety schedule and stopping criteria. The existing monitoring framework cannot simply be transferred to a new combination. Assessment should also distinguish hepatocellular enzyme changes from impaired synthetic function, symptoms, and bilirubin elevation, which have different implications



for the seriousness of an adverse reaction. [5]

Experimental injury and the limits of mechanistic inference

Animal studies identify biological changes that routine clinical testing cannot resolve. Daye and colleagues investigated isotretinoin-associated oxidative damage in rats and assessed liver, muscle, and blood during different exposure periods. Their findings support oxidative injury as a plausible component of retinoid-associated tissue stress. Markers such as lipid peroxidation products, protein oxidation, and oxidative DNA lesions provide complementary information; none independently establishes the complete causal sequence. Species differences and exposure duration also matter. A nominally comparable dose does not guarantee equivalent circulating metabolites or tissue concentrations. Experimental findings should therefore generate specific mechanistic questions rather than be used to predict the frequency of serious hepatic injury in acne patients. [6]

Taziki and colleagues provide more direct evidence that isotretinoin-associated oxidative disturbances can be modified experimentally. Taurine coadministration reduced injury-related changes in a rat model, supporting the possibility that antioxidant defenses participate in the hepatic response. This is relevant to green tea because it shows that tissue injury need not be pharmacologically immutable. It does not establish interchangeability between taurine and catechins, whose absorption, metabolism, signaling effects, and safety profiles differ. The appropriate inference is that redox-directed intervention deserves testing. A stronger claim, that any antioxidant preparation will reproduce the benefit, would exceed the evidence and obscure potentially important differences between compounds and experimental conditions. [7]

Retinoid signaling and male reproductive outcomes

Reproductive interpretation requires acknowledging that retinoic acid is necessary for germ-cell development. Koubova and colleagues demonstrated its involvement in the regulation of STRA8 expression and meiotic initiation in mice. Their developmental work establishes that retinoid signaling is an instructive biological process, not simply a source of reproductive toxicity. Exogenous isotretinoin may alter this system through exposure-dependent changes in active retinoid availability, but the direction of the response cannot be assumed in advance. The physiological role of retinoids helps explain why deficient signaling, excessive exposure, and treatment of selected infertile populations can produce different outcomes. It also argues against treating all retinoid-associated reproductive observations as evidence of a common toxic mechanism. [8]

In a prolonged rat study, Çırakoğlu and colleagues reported lower sperm count, motility, and vitality, reduced seminiferous tubular dimensions and germinal epithelial thickness, and an increased apoptotic index after isotretinoin administration. These concordant functional and morphological observations strengthen the experimental injury signal beyond a hormone measurement alone. Serum testosterone did not necessarily track the structural changes, demonstrating that circulating endocrine indices cannot exclude local testicular effects. Translation still requires attention to dose, exposure duration, developmental stage, and recovery after withdrawal. Findings from one animal protocol should not be presented as a quantified risk of infertility in men receiving ordinary acne treatment. [9]

Human evidence is less uniform. Gurel and colleagues studied semen parameters before and after systemic isotretinoin therapy, including assessment of varicocele. Several semen indices improved, whereas sperm morphology deteriorated; changes were more prominent in participants with varicocele. This combination resists a simple protective-versus-toxic classification. Improvements in concentration or motility do not establish increased fertility, while a morphological change does not by itself demonstrate permanent reproductive impairment. The study also shows why baseline reproductive status must be documented. Varicocele, pre-existing subfertility, abstinence interval, and within-person semen variability may influence apparent drug effects and should be incorporated into the interpretation of future studies. [10]

A pilot investigation by Amory and colleagues deliberately used isotretinoin to treat men with infertility associated with oligoasthenozoospermia. Sperm production improved in some participants, consistent with the physiological contribution of retinoid signaling to spermatogenesis. The single-arm design and



selected population limit causal inference and prevent generalization to otherwise fertile acne patients. Still, these findings are clinically important for a critical review because they contradict the assumption that systemic isotretinoin invariably suppresses sperm production. A protective intervention must preserve appropriate retinoid-dependent differentiation rather than merely reduce every downstream signal associated with exposure. The desired outcome is maintained reproductive function, not indiscriminate suppression of retinoid activity. [11]

A subsequent pilot study explored isotretinoin in nonobstructive azoospermia, extending the clinical hypothesis to a more severely affected population. This work remains exploratory and does not establish routine infertility treatment. Its relevance here is conceptual: reproductive response depends on the underlying biological state. Evidence from azoospermia, acne cohorts, and healthy laboratory animals addresses different questions and should be analyzed separately. A future catechin study cannot assume that the same adjunct will benefit all three groups. Baseline semen phenotype and treatment indication should therefore define eligibility, while repeated measurements and post-treatment follow-up are needed to distinguish transient changes from sustained improvement or persistent adverse effects. [12]

Green tea polyphenols as pharmacological exposures

Green tea contains multiple catechins, including epigallocatechin gallate, epigallocatechin, epicatechin gallate, and epicatechin. Epigallocatechin gallate receives particular attention because of its abundance and experimentally observed biological activity. Brewed tea, aqueous extracts, decaffeinated preparations, and purified catechins are not equivalent interventions. Their catechin proportions, caffeine content, accompanying constituents, and delivery patterns differ. Suzuki and colleagues describe a broad experimental literature on green tea, but these general biological properties should not be mistaken for indication-specific efficacy. For isotretinoin research, the preparation must be chemically characterized so that any observed effect can be linked to a reproducible exposure rather than the nonspecific label of green tea extract. [13]

Oral pharmacokinetics impose a major translational constraint. Chow and colleagues demonstrated that administering a defined catechin preparation in the fasting state increased the maximum plasma concentration of free epigallocatechin gallate by more than 3.5-fold compared with administration with food. Nutritional conditions can therefore alter systemic exposure even when the nominal dose is unchanged. Higher bioavailability is not automatically desirable for a protective intervention because the same increase may narrow the safety margin. Studies should report meal timing and measure exposure where feasible. Concentrations used in isolated cells should also be compared with achievable circulating and tissue concentrations before their effects are interpreted as likely consequences of oral supplementation. [14]

Catechin redox chemistry is similarly context dependent. Lambert and Elias explain that green tea polyphenols can quench radicals and chelate metals, but can also undergo oxidation and generate reactive species under particular conditions. Some apparent antioxidant effects may reflect induction of endogenous defenses following a limited stress response rather than direct scavenging alone. This dual behavior makes concentration, medium composition, metal availability, and cellular antioxidant reserve important experimental variables. It also provides a mechanistic reason to expect a non-linear relationship between dose and benefit. Increasing extract exposure may move the response from adaptive signaling toward injury instead of progressively improving protection. [15]

Hepatic protection beyond direct radical scavenging

Evidence from chemically induced liver injury supports several pathways that may be relevant to isotretinoin. Mostafa-Hedeab and colleagues found that epigallocatechin gallate improved biochemical and histological changes in a carbon tetrachloride model, with effects involving oxidative stress, inflammatory markers, and TGF β -associated signaling. Changes in phosphorylated ERK and Smad proteins provide stronger pathway information than transcript measurements alone. The model supports pharmacological plausibility, but carbon tetrachloride metabolism and fibrogenic injury differ from routine isotretinoin exposure. Its findings should therefore be used to nominate candidate mechanisms and endpoints rather than claim demonstrated protection against retinoid-associated hepatic toxicity or



its clinical complications. [16]

Zhou and colleagues studied epigallocatechin gallate in thioacetamide-induced hepatic encephalopathy and reported improvements involving antioxidant enzymes, inflammatory signaling, intestinal barrier proteins, and the microbiota–gut–liver axis. Modulation of Nrf2 and TLR4/NF- κ B suggests that catechins can influence coordinated stress responses beyond direct chemical neutralization of reactive species. This broader framework is relevant because systemic inflammation and intestinal signaling can amplify hepatic injury. However, severe thioacetamide-associated disease is biologically distinct from modest transaminase changes during acne treatment. Microbiota modification remains an indirect hypothesis for isotretinoin coadministration and should be identified as such, rather than presented as a mechanism already established in that setting. [17]

Limited human evidence from other liver disorders supplies additional context without resolving the isotretinoin question. Pezeshki and colleagues randomized patients with nonalcoholic fatty liver disease to green tea extract or placebo and reported improvements in liver enzyme measures during a short intervention. Such findings show that hepatic responses to extracts need not always be adverse, but effects in metabolic fatty liver cannot establish prevention of drug-induced injury. Differences in underlying disease, weight change, preparation, and catechin exposure may influence the result. The clinical inference should remain narrow: some preparations have shown biochemical benefit in a selected population, while efficacy and safety during isotretinoin treatment remain unproven. [18]

Reproductive protection and competing biological effects

Opuwari and Monsees investigated aqueous green tea consumption in male rats and observed increased sperm concentration and viability without significant changes in testosterone or several organ-related measures. These findings support a potential reproductive benefit under the conditions studied, while suggesting that improved sperm indices need not depend on increased androgen production. The intervention was an infusion consumed over time, not a purified catechin bolus. Moreover, the animals were not subjected to isotretinoin-associated injury. The study therefore provides evidence of a favorable reproductive response to a particular preparation, but it cannot demonstrate rescue of retinoid-induced damage or establish the safety of all concentrated extracts. [19]

Direct endocrine effects complicate the protective hypothesis. Figueiroa and colleagues reported that green tea extract and epigallocatechin gallate inhibited testosterone production in isolated rat Leydig cells under their experimental conditions. This finding is incompatible with describing catechins as uniformly steroidogenesis preserving. Protection of stressed Leydig cells and direct inhibition of steroid output can coexist because they represent different processes. A preparation might reduce oxidative injury while still altering enzyme activity or hormone synthesis. Future experiments should measure intratesticular steroidogenic function alongside circulating testosterone and tissue integrity, rather than assume that a favorable antioxidant marker guarantees preservation of androgen production. [20]

Other cellular findings point in the opposite direction. Yu and colleagues observed stimulation of testosterone production by selected catechins in rat Leydig cells at low concentrations, with evidence implicating cyclic adenosine monophosphate signaling. Taken together with the inhibitory study, these observations suggest that catechin identity, concentration, stimulation conditions, and experimental context influence endocrine effects. They do not justify selecting a clinically effective dose from isolated-cell experiments. The more useful conclusion is that reproductive pharmacology requires an explicit exposure-response analysis. A broad extract may also behave differently from its individual constituents, making chemical standardization and direct comparison of preparations especially important when steroidogenic outcomes are central. [21]

Human sperm experiments reinforce this concentration dependence. De Amicis and colleagues found that lower epigallocatechin gallate concentrations improved motility, viability, and selected metabolic and capacitation-related responses, whereas a higher concentration produced opposite effects. Estrogen receptor-associated signaling contributed to some favorable responses, showing that catechin activity extends beyond antioxidant chemistry. Because sperm were exposed directly *in vitro*, these results do not establish that oral supplementation produces comparable concentrations in the reproductive tract.



They do identify a potential therapeutic window and argue for measuring functional outcomes across several concentrations. Greater exposure should not be assumed to yield greater reproductive benefit, even when the intervention is derived from a familiar beverage. [22]

Physiological reactive oxygen species are required for aspects of sperm maturation, capacitation, and signaling. Dutta and colleagues describe the damaging effects of excessive oxidative stress but also the need for balanced redox activity. This distinction matters when interpreting a proposed antioxidant adjunct. Complete suppression of reactive species is not a meaningful reproductive objective, and improved total antioxidant capacity is not a substitute for fertilizing competence. Research should prioritize sperm function, DNA integrity, and recovery over isolated biochemical normalization. In clinical translation, pregnancy and live birth are more consequential than modest shifts in laboratory semen indices, although such endpoints require designs that address the contribution of both partners. [23]

The hepatic safety paradox of concentrated extracts

The liver is both a proposed target of catechin protection and an established site of extract-associated harm. The European Food Safety Authority concluded that supplementation providing 800 mg or more of epigallocatechin gallate daily was associated with increased serum transaminases in intervention studies. This observation is not a universal toxicity threshold and does not establish that every lower dose is safe. Traditional infusions and concentrated supplements also have different exposure profiles. These distinctions must be retained when evaluating an adjunct intended to prevent hepatic adverse effects. A protective hypothesis becomes clinically credible only when benefit is demonstrated at an exposure with an acceptable, independently characterized safety margin. [24]

The United States Pharmacopeia review similarly identifies green tea extract hepatotoxicity as a genuine safety issue and discusses factors including preparation and fasting-related exposure. Product characterization is therefore not an administrative detail; it is part of the pharmacological intervention itself. Total extract mass cannot reliably substitute for epigallocatechin gallate content, and batch variability can weaken reproducibility. For isotretinoin studies, reporting should include catechin composition, caffeine, extraction method, contaminants, and dosing conditions. A favorable result obtained with one standardized product should not be generalized to commercial supplements with different constituent profiles or labeling accuracy. Safety must be evaluated for the actual product used. [25]

Randomized evidence strengthens this concern. In the Minnesota Green Tea Trial, Dostal and colleagues studied a preparation supplying approximately 843 mg epigallocatechin gallate daily in postmenopausal women. Alanine aminotransferase elevations occurred more often with extract than with placebo, despite participant selection and prospective monitoring. The population differs from young acne patients, so its adverse-event frequency should not be transferred directly to isotretinoin coadministration. The trial demonstrates that extract-associated enzyme abnormalities are not confined to uncontrolled case reports. Its results require any proposed hepatoprotective use to include active adverse-event ascertainment rather than rely on the historical familiarity of tea consumption. [26]

A detailed analysis of liver outcomes from the same trial by Yu and colleagues found greater odds of moderate enzyme elevations with green tea extract. Because these publications arise from the same intervention, they should not be counted as independent replications. Their complementary analyses are still informative: repeated biochemical monitoring and changes after withdrawal help characterize the hepatic signal. For a future combination trial, both isotretinoin and extract exposure must be documented when abnormalities arise. Improvement after stopping both agents would not identify the responsible component. A predefined attribution process should consider timing, alternative causes, and the consequences of withdrawing each exposure. [27]

Pharmacovigilance adds evidence of host susceptibility. Hoofnagle and colleagues reported a strong association between HLA-B*35:01 and green tea-associated liver injury in the Drug-Induced Liver Injury Network. This finding supports an idiosyncratic, potentially immune-mediated component that cannot be explained solely by antioxidant capacity or nominal supplement dose. It also limits



reassurance derived from small healthy-animal studies, which cannot model the full diversity of human susceptibility. Genetic testing is not thereby established as routine screening for supplementation. Rather, the observation shows why absence of toxicity in a limited experimental population cannot establish that an extract is safe for all patients. [28]

Drug interaction and causal attribution

Botanical coadministration may change drug exposure as well as tissue response. Misaka and colleagues demonstrated a substantial reduction in nadolol concentrations after green tea ingestion in healthy volunteers, illustrating a clinically measurable interaction with a specific drug. This result does not demonstrate a corresponding interaction with isotretinoin. It does support requiring direct pharmacokinetic assessment before attributing lower injury markers exclusively to cytoprotection. If catechins reduce isotretinoin exposure, apparent protection could accompany reduced acne efficacy. Conversely, increased exposure could worsen adverse effects. Measurements of isotretinoin and relevant metabolites, together with treatment effectiveness, would distinguish these possibilities more reliably than biochemical injury markers alone. [29]

Priorities for experimental and clinical translation

Future animal studies should use randomized allocation, blinded outcome assessment, justified sample sizes, and complete reporting consistent with ARRIVE 2.0. A factorial design including vehicle, isotretinoin, extract alone, and the combination would distinguish baseline extract effects from modification of retinoid injury. Multiple exposures and a withdrawal phase would help define dose response and reversibility. These are proposed design priorities, not findings established by the reporting guideline. Studies should also identify the experimental unit, avoid treating multiple tissue fields as independent animals, and predefine primary outcomes. Such safeguards are essential when many biochemical, molecular, and histological comparisons are made within a small experiment. [30]

Mechanistic experiments should distinguish altered gene expression from demonstrated pathway activity. A change in an inflammatory transcript cannot establish nuclear translocation, and an apoptosis-related expression ratio cannot quantify completed cell death. Protein localization, phosphorylation, enzymatic activity, and tissue-specific functional measurements would provide more persuasive evidence. The proposed evaluation should also distinguish prevention during concurrent administration from treatment after injury has developed. These questions require different schedules and comparators. Finally, apparent restoration toward control values should be accompanied by effect estimates and uncertainty, rather than interpreted from a nonsignificant comparison alone. Failure to detect a difference does not establish equivalence, particularly when sample sizes are small and multiple outcomes are tested. These analytical distinctions would make a claimed protective mechanism more credible. [30]

The principal evidentiary limitation is the distance between mechanistic plausibility and demonstrated clinical protection. Improvements in oxidative markers obtained with another hepatotoxicant cannot establish prevention of isotretinoin injury, and better sperm indices in healthy rats cannot establish restoration of human fertility. The reviewed evidence supports a staged research program: characterize the preparation, establish exposure and safety, demonstrate reproducible functional benefit in the relevant model, and then evaluate a defined clinical indication. The contrasting redox and endocrine findings make negative results as informative as favorable ones. A critical synthesis should preserve these differences rather than merge them into a uniform claim of protection. [15,22]

Conclusion

Green tea polyphenols offer a plausible experimental approach to modifying oxidative and inflammatory components of isotretinoin-associated hepatic and testicular injury. Their effects depend on exposure, preparation, tissue context, and baseline reproductive function. Human evidence does not support a uniform model of isotretinoin-induced infertility, while concentrated catechin extracts carry an independent hepatic risk. Available findings therefore support further investigation rather than routine protective supplementation. Translation requires standardized products, pharmacokinetic characterization, reproducible functional outcomes, and controlled evaluation of both benefit and harm.



The most useful next step is to determine whether a safe catechin exposure preserves organ function during isotretinoin treatment without altering its therapeutic effectiveness in clinical practice.

References

1. Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. *J Am Acad Dermatol*. 2024;90(5):1006.e1-1006.e30.
2. Layton A. The use of isotretinoin in acne. *Dermatoendocrinology*. 2009;1(3):162-169.
3. Lee YH, Scharnitz TP, Muscat J, Chen A, Gupta-Elara G, Kirby JS. Laboratory monitoring during isotretinoin therapy for acne: a systematic review and meta-analysis. *JAMA Dermatol*. 2016;152(1):35-44.
4. Emtenani S, Abdelghaffar M, Ludwig RJ, Schmidt E, Kridin K. Risk and timing of isotretinoin-related laboratory disturbances: a population-based study. *Int J Dermatol*. 2024;63(12):1740-1747.
5. Xia E, Han J, Faletsky A, et al. Isotretinoin laboratory monitoring in acne treatment: a Delphi consensus study. *JAMA Dermatol*. 2022;158(8):942-948.
6. Daye M, Belviranli M, Okudan N, Mevlitoglu I, Oz M. The effect of isotretinoin therapy on oxidative damage in rats. *Dermatol Ther*. 2020;33(6):e14111.
7. Taziki S, Gholamzadeh F, Hosseini R. The hepatoprotective effects of taurine against oxidative stress induced by isotretinoin in rats. *J Biochem Mol Toxicol*. 2022;36(11):e23178.
8. Koubova J, Menke DB, Zhou Q, Capel B, Griswold MD, Page DC. Retinoic acid regulates sex-specific timing of meiotic initiation in mice. *Proc Natl Acad Sci U S A*. 2006;103(8):2474-2479.
9. Çirakoğlu A, Onder S, Hancı H, et al. Does isotretinoin affect spermatogenesis in the long term? A rat model. *Arch Ital Urol Androl*. 2023;95(3):11502.
10. Gurel A, Gurel G, Fırat F, et al. Effect of systemic isotretinoin therapy on semen parameters. *Ann Med*. 2023;55(1):2207038.
11. Amory JK, Ostrowski KA, Gannon JR, et al. Isotretinoin administration improves sperm production in men with infertility from oligoasthenozoospermia: a pilot study. *Andrology*. 2017;5(6):1115-1123.
12. Amory JK, Muller CH, Walsh TJ. Isotretinoin for the treatment of nonobstructive azoospermia: a pilot study. *Asian J Androl*. 2021;23(5):537-540.
13. Suzuki Y, Miyoshi N, Isemura M. Health-promoting effects of green tea. *Proc Jpn Acad Ser B Phys Biol Sci*. 2012;88(3):88-101.
14. Chow HH, Hakim IA, Vining DR, et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. *Clin Cancer Res*. 2005;11(12):4627-4633.
15. Lambert JD, Elias RJ. The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. *Arch Biochem Biophys*. 2010;501(1):65-72.
16. Mostafa-Hedeab G, Ewaiss Hassan M, Halawa TF, Wani FA. Epigallocatechin gallate ameliorates tetrahydrochloride-induced liver toxicity in rats via inhibition of TGFβ/p-ERK/p-Smad1/2 signaling, antioxidant, anti-inflammatory activity. *Saudi Pharm J*. 2022;30(9):1293-1300.
17. Zhou Z, Li K, Guo J, et al. Green tea catechin EGCG ameliorates thioacetamide-induced hepatic encephalopathy in rats via modulation of the microbiota-gut-liver axis. *Mol Nutr Food Res*. 2023;67(8):e2200821.
18. Pezeshki A, Safi S, Feizi A, Askari G, Karami F. The effect of green tea extract supplementation on liver enzymes in patients with nonalcoholic fatty liver disease. *Int J Prev Med*. 2016;7:28.
19. Opuwari C, Monsees T. Green tea consumption increases sperm concentration and viability in male rats and is safe for reproductive, liver and kidney health. *Sci Rep*. 2020;10(1):15269.
20. Figueiroa MS, César Vieira JSB, Leite DS, et al. Green tea polyphenols inhibit testosterone production in rat Leydig cells. *Asian J Androl*. 2009;11(3):362-370.
21. Yu PL, Pu HF, Chen SY, Wang SW, Wang PS. Effects of catechin, epicatechin and epigallocatechin gallate on testosterone production in rat Leydig cells. *J Cell Biochem*. 2010;110(2):333-342.
22. De Amicis F, Santoro M, Guido C, Russo A, Aquila S. Epigallocatechin gallate affects survival and metabolism of human sperm. *Mol Nutr Food Res*. 2012;56(11):1655-1664.
23. Dutta S, Majzoub A, Agarwal A. Oxidative stress and sperm function: a systematic review on evaluation and management. *Arab J Urol*. 2019;17(2):87-97.
24. EFSA Panel on Food Additives and Nutrient Sources added to Food. Scientific opinion on the safety of green tea catechins. *EFSA J*. 2018;16(4):5239.
25. Oketch-Rabah HA, Roe AL, Rider CV, et al. United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts. *Toxicol Rep*. 2020;7:386-402.
26. Dostal AM, Samavat H, Bedell S, et al. The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial. *Food Chem Toxicol*. 2015;83:26-35.
27. Yu Z, Samavat H, Dostal AM, et al. Effect of green tea supplements on liver enzyme elevation: results from a randomized intervention study in the United States. *Cancer Prev Res (Phila)*. 2017;10(10):571-579.
28. Hoofnagle JH, Bonkovsky HL, Phillips EJ, et al. HLA-B*35:01 and green tea-induced liver injury. *Hepatology*. 2021;73(6):2484-2493.
29. Misaka S, Yatabe J, Müller F, et al. Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects. *Clin Pharmacol Ther*. 2014;95(4):432-438.
30. Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. *PLoS Biol*. 2020;18(7):e3000410.